566 related articles for article (PubMed ID: 24528057)
41. Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience.
Porcel JM; Civit C; Esquerda A; Salud A; Bielsa S
Arch Bronconeumol; 2017 Aug; 53(8):427-431. PubMed ID: 28237067
[TBL] [Abstract][Full Text] [Related]
42. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels.
Menard O; Dousset B; Jacob C; Martinet Y
Eur J Cancer; 1993; 29A(13):1806-9. PubMed ID: 8260229
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels.
Saraya T; Ohkuma K; Fujiwara M; Ishii H
Medicine (Baltimore); 2022 Jan; 101(1):e28517. PubMed ID: 35029914
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
45. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
47. Tumor markers in the diagnosis of malignant serous effusions.
Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
[TBL] [Abstract][Full Text] [Related]
48. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
50. [Diagnostic utility of carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma antigen in malignant pleural effusion].
Sánchez de Cos Escuín J; López Parra S; Disdier Vicente C; Martín Vicente MJ; Masa Jiménez JF; Domínguez Retortillo C
An Med Interna; 1996 Aug; 13(8):369-73. PubMed ID: 8983362
[TBL] [Abstract][Full Text] [Related]
51. Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions.
Wang M; Zhang Z; Wang X
Clinics (Sao Paulo); 2014; 69(12):799-803. PubMed ID: 25627990
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic value of MUC1 and EpCAM mRNA as tumor markers in differentiating benign from malignant pleural effusion.
Sun W; Li J; Jiang HG; Ge LP; Wang Y
QJM; 2014 Dec; 107(12):1001-7. PubMed ID: 24939190
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Lung Cancer; 2003 Jun; 40(3):289-94. PubMed ID: 12781427
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.
Trapé J; Sant F; Franquesa J; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Pérez C; Lopez J; Ros S; Esteve E; Pérez R; Aligué J; Gurt G; Catot S; Domenech M; Bosch J; Badal JM; Bonet M; Molina R; Ordeig J
Respir Res; 2017 May; 18(1):103. PubMed ID: 28545517
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
56. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
[TBL] [Abstract][Full Text] [Related]
57. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
58. Strategies for five tumour markers in the screening and diagnosis of female breast cancer.
Luo J; Xiao J; Yang Y; Chen G; Hu D; Zeng J
Front Oncol; 2022; 12():1055855. PubMed ID: 36755860
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
Miédougé M; Rouzaud P; Salama G; Pujazon MC; Vincent C; Mauduyt MA; Reyre J; Carles P; Serre G
Br J Cancer; 1999 Nov; 81(6):1059-65. PubMed ID: 10576665
[TBL] [Abstract][Full Text] [Related]
60. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]